中国输血杂志2025，Vol.38Issue(12)：1702-1706,1734,6.DOI:10.13303/j.cjbt.issn.1004-549x.2025.12.008
特异性尿酸吸附血液灌流器去除难治性痛风患者血尿酸的有效性及安全性评价
A prospective clinical study on the efficacy and safety of specific uric acid adsorption hemoperfusion in removing se-rum uric acid from patients with refractory gout
LI Ying 1YANG Yuanming 1JING Zhongcui 1LIU Jiao 1JIANG Dandan 2YU Shanshan 1WANG Haiyan1
作者信息
- 1. Department of Blood Transfusion,the Affiliated Hospital of Qingdao University,Qingdao 266003,China
- 2. Department of Blood Transfusion,Huangdao District People's Hospital,Qingdao 266400,China
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of the single-use hemoperfusion device(UA230)in treating refractory gout(RG)via plasma perfusion.Methods Thirty-four RG patients aged 18-65 years were recruited and ran-domly divided into a control group(febuxostat therapy,n=17)and an experimental group(plasma perfusion combined with febuxostat therapy,n=17).Differences in serum uric acid(SUA)levels and urate-lowering rates between the two groups were analyzed using t-tests.Between-group differences in incidence of adverse reactions were analyzed using chi-square tests.Results At 7 and 14 days post-treatment,SUA levels in the experimental group were significantly lower than those in the control group,with a higher urate-lowering rate(all P＜0.05).However,no statistically significant differences in SUA levels or urate-lowering rate were observed at 28 days post-treatment(all P＞0.05).The incidence of adverse reactions showed no significant difference between the two groups(x2=0.15,P＞0.05).Conclusion The single-use hemoperfusion device(UA230),combined with plasma perfusion technology,is a safe and effective treatment for RG.It may serve as a no-vel therapeutic approach for RG patients in clinical practice.关键词
血浆灌流/难治性痛风/有效性/安全性Key words
plasma perfusion/refractory gout(RG)/efficacy/safety分类
医药卫生引用本文复制引用
LI Ying,YANG Yuanming,JING Zhongcui,LIU Jiao,JIANG Dandan,YU Shanshan,WANG Haiyan..特异性尿酸吸附血液灌流器去除难治性痛风患者血尿酸的有效性及安全性评价[J].中国输血杂志,2025,38(12):1702-1706,1734,6.
